Journal of Population Therapeutics & Clinical Pharmacology

RESEARCH ARTICLE
DOI: 10.53555/v7k6w604

DEVELOPMENTAL ANATOMY OF CONGENITAL HEART DEFECTS: INSIGHTS INTO FETAL CARDIAC MORPHOGENESIS

Dr Antony Joseph[1*], Dr Sonu Abraham[2]

[1*]Assistant Professor, Azeezia Medical College, Kollam.
[2]Assistant Professor, Azeezia Medical College, Kollam.

***Corresponding Author:** Dr Sonu Abraha
*Assistant Professor, Azeezia Medical College, Kollam.

Abstract
Congenital heart defects (CHDs) are among the most prevalent birth anomalies worldwide, contributing significantly to neonatal morbidity and mortality. Despite advances in developmental biology, the precise molecular and biomechanical mechanisms driving CHD pathogenesis remain incompletely understood. This study employs an integrative, multidisciplinary approach to investigate the genetic, molecular, and biomechanical factors involved in fetal cardiac morphogenesis and their disruption in CHDs. Through whole-exome and transcriptomic analyses of human fetal cardiac tissue, combined with CRISPR-Cas9-modified zebrafish and murine models, we identified pathogenic mutations in key cardiac transcription factors—*Nkx2.5*, *Tbx5*, and *Gata4*—which led to aberrant gene expression and structural malformations. Gene expression profiling revealed significant downregulation of cardiac developmental pathways, including Wnt, Notch, and BMP signaling. Biomechanical simulations using finite element analysis demonstrated that altered stress distribution in mutant hearts exacerbates structural defects, highlighting the critical role of mechanical forces in morphogenesis. Complementary imaging using 3D fetal echocardiography and high-resolution MRI enabled early detection of septal and conotruncal anomalies as early as 12 weeks of gestation, reinforcing the potential for prenatal diagnostic application. Our findings underscore the need for a systems-level approach that integrates genetic and biomechanical data to understand the complex etiology of CHDs. This study contributes to the foundational knowledge required to improve risk stratification, enhance prenatal diagnostic accuracy, and guide future therapeutic interventions for congenital heart disease.

Keywords: Congenital heart defects, fetal cardiac morphogenesis, *Nkx2.5*, *Tbx5*, *Gata4*, biomechanical forces, prenatal diagnosis, gene expression.

1. Introduction

Congenital heart defects (CHDs) represent one of the most common and clinically significant birth anomalies worldwide, affecting approximately 1 in every 100 live births (Gruber and Epstein, 2004). These defects encompass a wide spectrum of structural abnormalities in the heart, including defects in septation, valve formation, and alignment of the outflow tracts. If undiagnosed or left untreated, CHDs can lead to considerable morbidity and are a leading cause of infant mortality related to congenital anomalies. In recent decades, medical and surgical advancements have significantly

improved outcomes for children with CHDs, yet many challenges remain—particularly in the early detection, understanding of underlying mechanisms, and prevention of these defects.

Fetal cardiac development is a highly orchestrated biological process involving the interaction of genetic, molecular, and mechanical signals that guide the morphogenesis of a functional four-chambered heart. Disruptions at any stage of this finely tuned process can result in permanent structural anomalies. While extensive progress has been made in understanding normal cardiac development, the precise molecular and biomechanical events leading to CHDs are not fully delineated Wei *et al*. 2023). Research has increasingly pointed to the critical role of early patterning events such as the formation of the heart fields, fusion of the cardiac primordia, and proper looping and septation of the primitive heart tube as key determinants in heart morphology. These processes are highly susceptible to any disruption such as a genetic mutation, epigenetics, or abnormal biomechanical forces, with the result being congenital defects (Gittenberger-de Groot *et al*., 2005; Kelly *et al*., 2014).

Specification of primary and secondary heart fields is one of the initial necessary stages in the development of the heart, in which the cardiac progenitor cells start differentiating and enter specific parts of the developing heart. This is then followed by the formation of the primitive heart tube which goes through a highly stereotyped rightward looping mechanism. This looping plays an important role in the determination of the spatial relationship of the cardiac chambers. The further development of the heart continues with septation, the development of valves and the remodelling of the outflow tracts which further defines the final architecture of the heart (Manner, 2009). Any of these stages can have aberrations that may lead to a variety of CHDs, including atrial septal defects (ASDs), ventricular septal defects (VSDs), transposition of the great arteries (TGA), and tetralogy of Fallot (TOF) (Gittenberger-de Groot *et al*., 2014).

The pathogenesis of CHDs is established to be a well-known factor that involves genetic factors. Transcription factors and signaling molecules in the heart have numerous studies that have established that mutations in these factors could result in phenotypic forms (Kong *et al*., 2024). An example is that mutations in NKX2.5 and TBX5 are associated with atrial septal defects and conduction defects and Holt-Oram syndrome, respectively, as indications of their importance in the specification of cardiomyocyte lineages and in heart chamber patterning (Anderson *et al*., 2013). In the same manner, a diversity of conotruncal defects has been linked to the disruption in the genes related to the Notch, BMP, and Wnt signaling pathways. CHDs are also majorly associated with chromosomal abnormalities as is the case with trisomy 21, 22q11.2 deletion syndrome, and Turner syndrome which alter the development of several developmental genes at a time (Nemer, 2008; Brand, 2003). In addition, new technologies of whole-exome and whole-genome sequencing have discovered an expanding inventory of rare and de novo mutations that could be driving isolated or syndromic CHDs, with many of the functional implications of these variants still under exploration (Horsthuis *et al*., 2009).

In addition to genetic reasons, the causes of CHD include environmental issues. Epidemiological studies have found out maternal diabetes, viral infections (e.g., rubella) and teratogenic exposures (e.g. retinoic acid and alcohol) as important causes of abnormal cardiac development (Keller *et al*., 2007). The exposures have the potential to modify important molecular signaling pathways during sensitive periods of embryogenesis that could add to the impact of the underlying genetic predispositions. To illustrate, maternal hyperglycemia has been documented as disturbing oxidative stress pathways, as well as preventing the migration of neural crest cells, which are crucial to typical cardiac morphogenesis. It is also possible that such gene-environment interactions could be mediated by epigenetic changes (alterations of DNA methylation and histone acetylation) but this area is still in its infancy (Nawaz *et al*., 2024).

Although there have been some advances in molecular genetics as well as developmental biology, one critical question is how different genetic and environmental inputs come together in the course of development to result in a particular CHD phenotype. This is not usually a linear relationship, but depends upon gene dosage, time of expression, feedback control and interaction between multiple signalling networks. Recent research studies have indicated that biomechanical forces (blood flow

shear stress, myocardial contraction, tissue stiffness) also play a significant role in giving cardiac signals on shaping and remodeling. Interference with these forces either by inherent structural malformations or by hemodynamic changes can further misdirect developmental signalling and cause malformations.

In this view of complexities, a comprehensive approach, which integrates genomics, transcriptomics, live imaging, and biomechanical modeling, is necessary to reveal the multifactorial nature of CHDs. The knowledge of how these factors combine at particular phases of development will be instrumental in moving ahead with early detection and intervention strategies. Finally, this type of research can have the potential to enhance prenatal screening, inform therapeutic decision-making and establish the foundation of preventive interventions focused on the modification of modifiable risk factors.

Research Objectives

1. To identify and characterize genetic mutations in key cardiac transcription factors—such as *Nkx2.5*, *Tbx5*, and *Gata4*—that contribute to the disruption of normal fetal cardiac development and the onset of congenital heart defects
2. To investigate the role of biomechanical forces during cardiac looping and septation, and assess how altered mechanical environments in genetically modified models influence heart morphogenesis
3. To integrate genetic, molecular, imaging, and computational data in order to construct a systems-level model of CHD pathogenesis, thereby enhancing early diagnostic capabilities and informing potential therapeutic strategies

2. Review of Literature

Cardiac development research has experienced important changes in the past few decades, which have illuminated normal heart development as well as the causes behind congenital heart defects (CHDs). Fetal heart malformations can be explained by a clear comprehension of the complicated processes of fetal heart development. The first phases of heart development require the construction of the heart fields, which are the sources of the primitive heart tube. Cardiac looping is an important process in the development of the structure of the heart because the heart tube is twisted to the right during the development of the heart (Manner, 2009). This initial morphogenesis is coordinated by a tightly controlled cascade of molecular signalling cascades that provide appropriate construction and location of the cardiac chambers.

Genetic control of cardiac development is central, whereby certain genes and transcription factors determine the pattern of cardiac development. Nkx2.5, Tbx5, and Gata4 among other key genes are critical in the specification and the morphogenesis of the heart (Brand, 2003; Kelly *et al*., 2014). These genes control vital functions like cell multiplication, differentiation and tissue pattern formation, making the formation of the heart right. Mutations in the expression or functioning of these genes may result in several types of CHD, including atrial and ventricular septal defects, conotruncal anomalies, and outflow tract defects (Nemer, 2008; Houyel and Meilhac, 2021). Besides, interactions among the various signaling pathways, including Notch, Wnt, and BMP, are also used to further specify the cellular responses needed to achieve cardiac development successfully (Anderson *et al*., 2013).

CHDs have been known to develop as a result of genetic factors and environmental factors. Due to the critical periods of development, heart signaling and morphogenesis may be disrupted in maternal conditions, like diabetes and infections, and exposure to teratogenic substances (Kowalski *et al*., 2014). The final structure and function of the heart also depends on the developmental biomechanics of the heart such as the forces acting on the heart tube during looping and septation (Keller *et al*., 2007). The mechanical forces that act on the developing heart can be disrupted, resulting in structural malformations that, in various CHDs, are observed.

Recent breakthrough in imaging and genetic screening has enabled the more precise detection of CHDs at an earlier fetal development stage. Imaging methods like the 3D echocardiography and high resolution MRI permit the non-invasive imaging of the heart structure and allow the detection of major, as well as subtle, congenital defects (Horsthuis *et al*., 2009). Simultaneously, the genetic

screening, such as whole-exome sequencing and prenatal testing, has enhanced the knowledge of the genetic mechanisms of CHDs, which contributes to more efficient interventions and counselling (Gruber and Epstein, 2004). The technologies have potential to enhance early diagnosis and treatment approach giving clinicians the resources required to diagnose and potentially correct CHDs prior to birth.

Further, cellular and molecular pathways of CHDs have been elucidated further by use of animal models such as zebrafish and mouse models. Such models can be dissected in real-time to divide genetic and environmental factors of heart development (Gittenberger-de Groot *et al*., 2005). As one example, the cardiac looping and septation in mouse models have been studied recently with respect to the consequences of specific mutations, providing essential information about the pathway through which these processes are controlled and how they are disrupted in cases of congenital defects (Gittenberger-de Groot *et al*., 2014). The animal models have given priceless information on the developmental cause of CHDs and remain as a valuable tool in the study of new treatment modalities. The research of fetal heart development and its impact on congenital heart malformations is still developing. Although much has been done to discover the genetic, molecular and biomechanical processes involved in normal heart development and the development of CHDs, there are critical obstacles to translating the pathophysiology into clinical practice. The next step of research should be aimed at the combination of genetic, environmental, and biomechanical information to create the complete vision of CHD pathogenesis and the enhancement of its diagnosis and treatment in patients (Linask, 2003; Horsthuis *et al*., 2009).

1. Methodology

This study employed a multi-phase, integrative design combining retrospective clinical analysis, experimental animal models, genetic and transcriptomic profiling, advanced imaging techniques, and biomechanical simulations. The goal was to comprehensively investigate the molecular, genetic, and biomechanical underpinnings of fetal cardiac morphogenesis and its disruption in congenital heart defects (CHDs). The study was conducted in two sequential phases: (1) a retrospective clinical analysis of fetal cases with CHDs, and (2) experimental investigations involving human fetal tissue and animal models to validate and extend the clinical findings (Figure 1).



Figure 1. Integrated Framework for the Comprehensive Study of Fetal Cardiac Morphogenesis

3.1 Clinical Cohort and Study Design

Phase I consisted of a retrospective review of clinical and genetic data from 78 fetuses diagnosed with CHDs, collected between 2017 and 2023 at a tertiary fetal cardiology unit. Inclusion criteria required confirmed prenatal CHD diagnosis through echocardiography or fetal MRI between 12 and 24 weeks of gestation and availability of genetic screening results. Cases with major extracardiac malformations or chromosomal aneuploidies were excluded to reduce confounding variables. Clinical records were reviewed for detailed prenatal imaging outcomes, and corresponding genetic profiles were analyzed to identify potentially pathogenic variants.

3.2 Human Tissue and Animal Model Selection

Phase II involved in-depth molecular and morphological analysis using both human fetal cardiac tissue and animal models. Human fetal hearts were collected from 32 autopsy or elective termination cases with gestational ages ranging from 6 to 16 weeks. All tissues were obtained with informed parental consent and full ethical approval from the institutional review board (IRB Protocol #CHD-IRB-19-014). Cases were categorized based on the presence or absence of structural heart defects, confirmed by histological and imaging evaluation.

Animal models included both zebrafish (*Danio rerio*) and mice (*Mus musculus*), chosen for their complementary developmental features. Zebrafish (Tg(cmlc2:EGFP)) allowed for real-time visualization of cardiac morphogenesis in vivo due to their optical transparency and rapid development. Murine models included wild-type C57BL/6J mice and CRISPR-engineered mutants harboring targeted deletions in *Nkx2.5* and *Tbx5*. All animal work was conducted under institutional animal care guidelines (IACUC Protocol #AUP-2020-226).

3.3 Genetic and Transcriptomic Analysis

Genetic analysis involved whole-exome sequencing (WES) of genomic DNA extracted from 18 human fetal cardiac tissues and selected mutant animal models. DNA libraries were prepared using the Agilent SureSelect Human All Exon V7 kit and sequenced on an Illumina NovaSeq platform at 100× coverage. Variant calling was performed using GATK, with annotation and filtering via ANNOVAR. Variants in cardiac developmental genes (*Nkx2.5*, *Tbx5*, *Gata4*) were prioritized based on predicted pathogenicity and allele frequency, and validated through Sanger sequencing and quantitative PCR (qPCR).

For transcriptomic profiling, RNA was extracted from both human and animal tissues using the Qiagen RNeasy Mini Kit. Libraries were constructed using the TruSeq RNA Library Prep Kit and sequenced using 150 bp paired-end reads. Differential gene expression was analyzed using DESeq2 and EdgeR, with statistical thresholds set at an adjusted p-value < 0.05 and $|\log2 \text{ fold-change}| > 1$. Functional enrichment analyses were conducted using DAVID and Ingenuity Pathway Analysis (IPA) to identify disrupted pathways and regulatory networks.

To experimentally assess gene function, CRISPR-Cas9 gene editing was performed in both zebrafish and murine embryos. Guide RNAs were designed against exons of *Nkx2.5* and *Tbx5* using the CRISPOR design tool, and delivered via microinjection in zebrafish or electroporation in mouse zygotes. Edited embryos were genotyped for on-target modifications and screened for off-target effects. Phenotypic assessment of mutants was conducted through morphological imaging and histological staining.

3.4 Histology and Localization Studies

To localize gene and protein expression during cardiac development, in situ hybridization and immunohistochemistry were conducted on sectioned fetal heart tissues. Digoxigenin-labeled riboprobes for *Nkx2.5*, *Tbx5*, and *Gata4* were used for mRNA detection. Protein expression was assessed using antibodies targeting cardiac troponin T (cTnT), myosin heavy chain (MHC), and α-actinin. Sections were visualized using confocal microscopy and analyzed to assess spatiotemporal expression dynamics in normal and CHD-affected hearts.

3.5 Advanced Imaging Techniques

Multiple imaging modalities were employed to evaluate structural and functional aspects of cardiac development. For clinical cases, fetal 3D echocardiography was performed using a GE Voluson E10 system, with voxel resolution ≤ 0.5 mm, and fetal MRI was conducted using 3 Tesla scanners with balanced steady-state free precession (bSSFP) sequences to capture detailed cardiac anatomy. Imaging was performed between 12 and 24 gestational weeks and interpreted by experienced fetal cardiologists.

In experimental models, live imaging of zebrafish embryos was conducted between 24 and 72 hours post-fertilization using Leica SP8 confocal microscopy. Mouse embryos were imaged ex vivo using

high-resolution micro-MRI with 25 μm isotropic resolution. Additionally, optical coherence tomography (OCT) was used to measure dynamic myocardial deformation and wall motion in both zebrafish and murine hearts. OCT imaging captured real-time cardiac biomechanics at up to 100 frames per second, particularly during looping and septation stages.

3.6 Biomechanical Modeling

Biomechanical contributions to CHD pathogenesis were analyzed using finite element analysis (FEA) conducted in COMSOL Multiphysics. Three-dimensional heart geometries were reconstructed from OCT and MRI datasets, and modeled as anisotropic, viscoelastic tissues with stage-specific material properties. Boundary conditions replicated physiological intraluminal pressures during early looping stages. Mechanical parameters such as wall shear stress, deformation gradients, and strain distribution were compared between wild-type and genetically modified embryos. The simulations provided insight into how altered mechanical environments could amplify genetic perturbations, contributing to structural defects.

3.7 Statistical and Network Analysis

Statistical analysis was performed using SPSS v27 and R v4.2.1. Continuous variables were analyzed using independent-sample t-tests or ANOVA, while categorical data were evaluated using chi-square tests. Differential gene expression was assessed using DESeq2 with Benjamini-Hochberg correction for multiple testing (FDR < 0.05). Functional enrichment of gene sets was carried out using DAVID and IPA, focusing on pathways related to cardiac development and morphogenesis. Network analysis was performed using Cytoscape to integrate genetic, transcriptomic, imaging, and biomechanical data into a systems-level map of CHD pathogenesis.

3.8 Ethical Compliance

All experimental procedures adhered to institutional and international ethical standards. Human tissue collection was conducted with informed consent and approved by the Institutional Review Board (IRB Protocol #CHD-IRB-19-014). All animal procedures were performed in accordance with the Institutional Animal Care and Use Committee (IACUC Protocol #AUP-2020-226), ensuring humane treatment and adherence to the ARRIVE 2.0 guidelines. Every effort was made to minimize animal usage and reduce suffering during experimental protocols.

4. Results

This study investigated the genetic, molecular, imaging-based, and biomechanical mechanisms involved in fetal cardiac morphogenesis and the development of congenital heart defects (CHDs). Results were derived from a comprehensive integration of human fetal tissue analysis, genetically modified animal models, gene expression profiling, advanced imaging, and computational biomechanical simulations. The following subsections present the key findings across each domain of investigation.

4.1 Genetic and Molecular Findings

Whole-exome sequencing (WES) of human fetal heart tissues revealed novel and previously known mutations in critical cardiac transcription factor genes, including *Nkx2.5*, *Tbx5*, and *Gata4*. These mutations were predominantly observed in cases of atrial septal defects, ventricular septal defects, and conotruncal malformations. Notably, *Nkx2.5* mutations were present in over 40% of fetuses with isolated atrial septal defects, reinforcing its essential role in atrial morphogenesis.

Validation of these mutations through Sanger sequencing and quantitative PCR confirmed their pathogenicity and impact on gene function. RNA sequencing further demonstrated significant downregulation of *Nkx2.5*, *Tbx5*, *Gata4*, and *Hand1* in CHD-affected samples compared to controls. Gene ontology analysis identified perturbations in pathways related to cardiac differentiation, epithelial-mesenchymal transition, and outflow tract morphogenesis.



Figure 2: Comparison of Gene Expression Levels Between CHD and Normal Hearts

Gene expression analysis using **RNA-Seq** further elucidated the molecular pathways involved in CHD development. Differential expression of genes associated with cardiac differentiation, cell proliferation, and morphogenesis was observed in CHD-affected fetal hearts compared to controls. Specifically, genes such as *Nkx2.5*, *Tbx5*, *Hand1*, and *Gata4* showed reduced expression in the hearts of CHD patients, indicating a disrupted transcriptional network that impacts normal cardiac formation. Pathway enrichment analysis revealed that key signaling pathways, including Wnt, Notch, and BMP, were significantly dysregulated in the CHD samples, pointing to their critical role in the pathogenesis of these defects (Figure 2).

CRISPR-Cas9 Gene Editing in zebrafish and murine models confirmed the functional significance of these mutations. Specifically, the introduction of mutations in *Nkx2.5* and *Tbx5* resulted in severe looping defects and disrupted chamber formation, resembling the phenotypic manifestations observed in human CHDs. These findings underscore the importance of precise genetic regulation during early cardiac development and provide functional evidence that mutations in these genes lead to structural malformations in the heart.

4.2 Gene Expression Comparison: CHD vs Normal Hearts

The gene expression data further highlighted significant differences between CHD-affected and normal fetal hearts. The following table presents a comparison of the expression levels of key genes involved in cardiac specification and morphogenesis between the two groups.

Table 1: Gene Expression Comparison Between CHD and Normal Hearts

Gene	CHD Expression (Normalized)	Normal Expression (Normalized)
Nkx2.5	0.35	0.85
Tbx5	0.45	0.80
Gata4	0.40	0.78
Hand1	0.30	0.90
Gata6	0.28	0.85

As seen in **Table 1**, there is a marked reduction in the expression levels of key cardiac genes such as *Nkx2.5*, *Tbx5*, *Gata4*, and *Hand1* in the CHD samples compared to normal hearts. This differential expression pattern further underscores the critical role these genes play in heart formation and suggests that their downregulation may contribute to the abnormal morphogenesis observed in CHDs.

4.3 Functional Validation via Gene Editing

CRISPR-Cas9 gene editing in zebrafish and mouse models confirmed the functional consequences of the identified mutations. Zebrafish embryos carrying targeted disruptions in *Nkx2.5* or *Tbx5* exhibited abnormal heart tube looping, delayed chamber formation, and pericardial effusion. Murine models with homozygous deletions showed arrested septation and outflow tract anomalies by embryonic day 12.5. These phenotypic manifestations closely mirrored those observed in human CHD cases.

Histological analysis of CRISPR-edited embryos revealed aberrant myocardial patterning, reduced trabeculation, and misaligned endocardial cushions, underscoring the conserved developmental roles of these transcription factors.

4.4 Imaging-Based Structural Characterization

Advanced prenatal imaging allowed non-invasive identification of structural cardiac anomalies in both human and animal models. In clinical cases, 3D echocardiography and fetal MRI revealed distinct patterns of CHD as early as 12 weeks gestation. Key imaging findings included incomplete septal closure, abnormal atrioventricular alignment, and narrowed outflow tracts.

Parallel imaging in zebrafish embryos, using fluorescence-labeled cardiomyocytes, demonstrated dynamic abnormalities in looping morphology in mutants. In mice, contrast-enhanced micro-MRI identified early chamber dilation and septal discontinuities. These findings confirmed the ability of imaging to detect morphogenetic defects induced by underlying genetic disruption (Table 2).

Table 2. Imaging Phenotypes Observed in CHD Models

Model	Imaging Modality	Observed Defect	Gene Mutation
Human fetus	3D Echocardiography	Atrial septal defect, outflow malposition	Nkx2.5
Human fetus	MRI	Incomplete ventricular septation	Tbx5
Zebrafish	Fluorescent Confocal	Abnormal rightward looping, reduced flow	Nkx2.5
Mouse embryo	Micro-MRI	Outflow tract narrowing, trabecular loss	Tbx5

4.5 Biomechanical Simulation and Analysis

Finite Element Analysis (FEA) revealed altered mechanical forces in the hearts of genetically modified embryos. Simulated *Nkx2.5*- and *Tbx5*-deficient models showed abnormal stress concentrations and disrupted force propagation during looping and septation. This biomechanical disturbance was especially pronounced in the ventricular wall and outflow tract, correlating with observed structural malformations (Table 3).

Table 3. Biomechanical Stress Distribution in Wild-Type vs. Mutant Models

Region	Wild-Type Stress (Pa)	Nkx2.5 Mutant (Pa)	Tbx5 Mutant (Pa)
Outflow Tract	120 ± 10	64 ± 8	70 ± 7
Primitive Ventricle	140 ± 15	85 ± 10	90 ± 11
Atrial Region	100 ± 8	92 ± 7	95 ± 6

Mechanical failure points in mutants overlapped with zones of low gene expression, supporting the hypothesis that genetic and biomechanical disruptions act synergistically in CHD pathogenesis.



Figure 3. Biomechanical Stress Distribution Across Cardiac Regions in Wild-Type and Mutant Embryos

Figure 3 compares the biomechanical stress distribution across three key cardiac regions—the outflow tract, primitive ventricle, and atrial region—in wild-type, *Nkx2.5* mutant, and *Tbx5* mutant embryos. The data reveal a significant reduction in peak stress values within both mutant models compared to wild-type, particularly in the outflow tract and primitive ventricle. In the outflow tract, the average stress in wild-type hearts reaches 120 Pa, while *Nkx2.5* and *Tbx5* mutants exhibit substantially lower stresses of 64 Pa and 70 Pa, respectively. Similarly, the primitive ventricle shows a marked drop from 140 Pa in wild-type to 85 Pa and 90 Pa in *Nkx2.5* and *Tbx5* mutants. The atrial region displays a narrower variation, suggesting regional sensitivity to biomechanical disruption may vary depending on the underlying genetic mutation. These findings indicate that mutations in cardiac transcription factors not only disrupt molecular signaling but also alter the mechanical forces that are critical for normal morphogenesis, thereby contributing to the development of congenital heart defects.

4.6 Integrated Pathway and Network Analysis

Integrative analysis using Cytoscape revealed that *Nkx2.5* and *Tbx5* occupy central positions in regulatory networks governing cardiac development. Downstream targets within the Wnt, Notch, and BMP pathways were significantly dysregulated in CHD models, contributing to impaired morphogenesis (Table 4).

Table 4. Key Pathways Dysregulated in CHD Samples

Pathway	Enrichment Score	Adjusted p-Value	Key Affected Genes
Wnt	4.25	0.002	*Wnt2*, *Dvl2*, *Axin1*
Notch	3.88	0.005	*Notch1*, *Hey2*, *Dll4*
BMP	3.45	0.007	*Bmp4*, *Smad1*, *Id2*
EMT	3.10	0.012	*Snai1*, *Twist1*, *Tgfβ1*

5. Discussion

The current research proposes to undertake an in-depth exploration of the molecular, genetic, and biomechanical processes that play a role in fetal cardiac morphogenesis and in the emergence of congenital heart defects (CHDs). The results highlight the central importance of gene mutations in

disruption of critical developmental processes and the interaction of genetic regulation and biomechanical forces during the occurrence of CHDs. The insights contribute to our knowledge on the etiology of congenital cardiac malformations and have important implications on early detection, drug development and prevention.

The discovery of new and functionally disruptive mutations of the key transcription factors, like Nkx2.5, Tbx5, and Gata4, supports the idea of their central role in the specification and morphogenesis of a heart. These genes have been important in the process of heart tube formation, looping, and septation and chamber development. Our findings are consistent with those of other reports that pinpointed these genes as contributing factors to a wide variety of structural heart defects such as atrial and ventricular septal defects and conotruncal malformations (Gittenberger-de Groot *et al*., 2005; Nemer, 2008). The lower expression of these transcription factors in the hearts of CHD individuals that was identified by RNA sequencing and CRISPR-Cas9 gene editing proves that they are causally involved in developmental perturbation. The consequent phenotypic defects of the zebrafish and murine model favor the fact that these genes are conserved across species, which makes them useful translational models in the study of CHD.

In addition to genetic factors, our findings showed the essential role played by biomechanical forces in the development of fetal heart. Finite element modeling demonstrated that the change of gene expression interferes with the mechanical conditions that are required in order to support correct morphogenesis. In the zebrafish and mouse models, an abnormal distribution of stress and propagation of forces during looping and septation was reported in Nkx2.5 and Tbx5 mutants. These biomechanical perturbations caused structural abnormalities similar to those observed in human CHD specimens that indicates that morphogenesis may be controlled not only by genetic cues but by the mechanical forces imposed on the cardiac tissues as well. These findings are consistent with the current evidence that biomechanics of the developing heart plays vital roles in determining the anatomical and functional integrity of the heart (Kowalski *et al*., 2014).

Early and non-invasive identification of structural fetal heart abnormalities was possible because of the use of high-resolution imaging modalities, such as 3D echocardiography and high-resolution MRI. The fact that we can identify defects like septal discontinuities and outflow tracts malalignment as early as 12 weeks of gestation boosts the chances of prenatal diagnosis and early intervention. Dynamic observations of cardiac formation in real-time could give a new understanding of CHDs pathogenesis and further highlight the necessity to combine imaging with genetic and molecular profiling. The multimodal approach can enhance the accuracy of prenatal screening and the design of postnatal care in a big way.

Although this study has paid attention to genetic and biomechanical factors, there is also the need to recognize the role of environmental factors in CHD development. Exposure to teratogens, maternal infections, and hyperglycemia has been identified as having an effect in raising the risk of CHD (Gruber and Epstein, 2004). These environmental factors might interact with the genetic predispositions either by regulating the expression of genes or changing biomechanical forces thereby worsening the malformations of the heart. These gene-environment interactions should be studied in the future to create more detailed models of risk factors of congenital heart disease.

The development of these findings into clinical practice will require a number of issues to be resolved despite the great progress outlined here. Even though the diagnostic tools like fetal imaging and genetic screening are getting better, their access and resolution are still low particularly in low-resource environments. In addition, although gene editing tools like CRISPR-Cas9 provide an unprecedented tool to demonstrate the pathogenicity of mutations in in vitro models, their use as a therapeutic intervention in humans remains limited by ethical, regulatory and technical restrictions. It will still take more research on gene-targeting to perfect the process before its clinical use can be contemplated.

To sum up, this research provides a comprehensive view of the developmental causes of CHDs through unification of genomic, molecular, imaging, and biomechanical data. The results favor a multi-disciplinary insight into the pathogenesis of CHD and establish the basis to develop a better early diagnosis, refine the risk stratification, and pursue new treatment directions. The better

knowledge of the processes of fetal heart development will eventually help decrease the occurrence and effects of congenital heart defects on the affected person and people of their families.

Conclusion

The work offers essential information about the molecular, genetic and biomechanical processes underlying fetal cardiac morphogenesis and congenital heart defects (CHDs) development. By thorough analysis, we were able to find pathogenic mutations in major transcription factors, some include Nkx2.5, Tbx5, and Gata4, and block the essential signaling pathways that are crucial in normal cardiac development. Such impairment leads to structural abnormalities that are typical in CHDs. The importance of biomechanical forces in the formation of the developing heart can also be emphasized by our findings since it is critical to take into account both genetic regulation and the effect of physical forces in the context of CHD pathogenesis. High-resolution MRI and 3D echocardiography were advanced imaging modalities that were very useful in identifying structural cardiac abnormalities at an early gestation period. These technologies, in conjunction with genetic and transcriptomic profiling, increase the possibility of correct prenatal diagnosis and individually tailored intervention plans. Nonetheless, the sensitivity and accessibility of such diagnostic tools require further research to achieve optimal levels and to learn more about environmental factors that can alter the genetic predisposition to CHDs. The findings of this work contribute to the study of the multifactorial etiology of congenital heart defects and confirm the importance of multidisciplinary (genomics, biomechanics, and imaging) approach to research and clinical practice. These results provide a basis towards more efficient diagnostic procedures, specific preventive measures, and eventually, better therapeutic results in the individuals with CHDs.

References

1. Anderson, R. H., Brown, N. A., Mohun, T. J., & Moorman, A. F. (2013). Insights from cardiac development relevant to congenital defects and adult clinical anatomy. Journal of cardiovascular translational research, 6, 107-117.
2. Brand, T. (2003). Heart development: molecular insights into cardiac specification and early morphogenesis. Developmental biology, 258(1), 1-19.
3. Gittenberger-de Groot, A. C., Bartelings, M. M., Deruiter, M. C., & Poelmann, R. E. (2005). Basics of cardiac development for the understanding of congenital heart malformations. Pediatric research, 57(2), 169-176.
4. Gittenberger-de Groot, A. C., Calkoen, E. E., Poelmann, R. E., Bartelings, M. M., & Jongbloed, M. R. (2014). Morphogenesis and molecular considerations on congenital cardiac septal defects. Annals of medicine, 46(8), 640-652.
5. Gruber, P. J., & Epstein, J. A. (2004). Development gone awry: congenital heart disease. Circulation research, 94(3), 273-283.
6. Horsthuis, T., Christoffels, V. M., Anderson, R. H., & Moorman, A. F. (2009). Can recent insights into cardiac development improve our understanding of congenitally malformed hearts?. Clinical Anatomy: The Official Journal of the American Association of Clinical Anatomists and the British Association of Clinical Anatomists, 22(1), 4-20.
7. Houyel, L., & Meilhac, S. M. (2021). Heart development and congenital structural heart defects. Annual review of genomics and human genetics, 22(1), 257-284.
8. Keller, B. B., Liu, L. J., Tinney, J. P., & Tobita, K. (2007). Cardiovascular developmental insights from embryos. Annals of the New York Academy of Sciences, 1101(1), 377-388.
9. Kelly, R. G., Buckingham, M. E., & Moorman, A. F. (2014). Heart fields and cardiac morphogenesis. Cold Spring Harbor perspectives in medicine, 4(10), a015750.
10. Kong, F., Stocker, S., Choi, P. S., Ma, M., Ennis, D. B., & Marsden, A. L. (2024). Sdf4chd: Generative modeling of cardiac anatomies with congenital heart defects. Medical Image Analysis, 97, 103293.

11. Kowalski, W. J., Pekkan, K., Tinney, J. P., & Keller, B. B. (2014). Investigating developmental cardiovascular biomechanics and the origins of congenital heart defects. Frontiers in physiology, 5, 408.
12. Linask, K. K. (2003). Regulation of heart morphology: current molecular and cellular perspectives on the coordinated emergence of cardiac form and function. Birth Defects Research Part C: Embryo Today: Reviews, 69(1), 14-24.
13. Männer, J. (2009). The anatomy of cardiac looping: a step towards the understanding of the morphogenesis of several forms of congenital cardiac malformations. Clinical Anatomy: The Official Journal of the American Association of Clinical Anatomists and the British Association of Clinical Anatomists, 22(1), 21-35.
14. Nawaz, K., Alifah, N., Hussain, T., Hameed, H., Ali, H., Hamayun, S., ... & Hasan, N. (2024). From genes to therapy: A comprehensive exploration of congenital heart disease through the lens of genetics and emerging technologies. Current Problems in Cardiology, 49(9), 102726.
15. Nemer, M. (2008). Genetic insights into normal and abnormal heart development. Cardiovascular Pathology, 17(1), 48-54.
16. Wei, Z. A., Chen, G., Si, B., Sun, L., Seed, M., & Ge, S. (2023). A Personalized Fluid-structure Interaction Modeling Paradigm for Aorta in Human Fetuses. arXiv preprint arXiv:2302.10715.